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Neurological manifestations of SARS-CoV-2 infection are increasingly being recognized. The most 
common neurologic symptoms include headache, anosmia, and dysgeusia, but patients may also develop 
other central nervous system (CNS) diseases. If we focus on the coronavirus family, there is clear evidence 
of its neurotropic character as demyelinating disease has been previously reported with MERS and SARS-
CoV-1 (Dessau, 2001). However, data remains limited in terms of cases of CNS post-infectious 
demyelinating/inflammatory disease following COVID-19. Recent studies have shown that the novel 
coronavirus appears to cross the blood-brain barrier and cause acute or delayed CNS demyelination or 
axonal damage (Desforges, 2020). A variety of mechanisms have been postulated including virus-induced 
hypercoagulable or pro-inflammatory states, direct viral invasion of the CNS, and post-infectious immune-
mediated processes. 
 
The first radiologic description of neurologic complications due to SARS-CoV-2 infection was described 
by Poyiadji et al.
 
with a case of acute necrotizing encephalopathy (ANE), probably related to virus-induced 
cytokine storm. For SARS CoV-2 infection, the pro-inflammatory state induced by the cytokine storm, 
mainly sustained by IL-1, IL-6, and TNF-α, may be responsible for the activation of glial cells with 
subsequent demyelination (Mehta, 2020). A possible alternative could be the production of antibodies 
against glial cells triggered by the virus, as a para-infectious or post-infectious phenomenon. 
 
Coronaviruses have been associated with other demyelinating pathologies like acute or subacute 
disseminated encephalomyelitis (ADEM) in humans (Yeh, 2004). ADEM is a rare acute inflammatory 
demyelinating disease that may follow viral infections. The first case of COVID-19 associated ADEM was 
described in a 40-year-old woman (Zhang, 2020). Another case of ADEM was reported in a 54-year-old 
woman following COVID-19 disease. SARS-CoV-2 was not detected in the CSF probably because the 
neurological damage was sustained by a delayed immune response occurring after the viremia (Zanin, 
2020). The first reported case of SARS-CoV-2 causing acute transverse myelitis was reported from Wuhan, 
China, where the outbreak first began, and the second case from Boston (Zhao 2020, Sarma 2020). Since 
then, a few cases from different parts of the world have also been reported. 
 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. The cause of MS is 
so far unknown, but both genetic and environmental factors are considered important. Environmental 
factors, especially viruses, have been associated with the development of demyelinating disease, but no 
specific agent has yet been definitively linked to MS. For example, Epstein-Barr virus infection is 
considered an important risk factor for the development of MS (Donati, 2020). SARS-CoV-2 may play a 
role of infective trigger, similar to the one of Epstein Barr virus in MS. The presence of demyelination, as 
well as SARS virus particles and genome sequences, in the brain has been detected in autopsy studies 
(Zhang, 2003). 
 
At Thomas Jefferson University Hospital, we recently described the first case of Neuromyelitis optica 
(NMO) potentially triggered by SARS-CoV-2 infection. NMO is a rare, inflammatory demyelinating 
disease of the CNS, predominantly affecting the optic nerves and spinal cord. NMO is diagnosed by the 
presence of at least 1 of 6 core clinical characteristics and detection of NMO/AQP4 IgG. The core clinical 
characteristics each implicate 1 of 6 CNS regions: optic nerve, spinal cord, area postrema of the dorsal 
medulla, brainstem, diencephalon, or cerebrum (Wingerchuk, 2015). Our patient met criteria for NMO 
based on the following 2 clinical characteristics: longitudinally extensive transverse myelitis (spinal cord 
lesion spanning greater than 3 segments) and area postrema syndrome (dorsal medullary lesion) in the 
setting of positive NMO/AQP-4 serum antibodies.  
 
In all forms of demyelinating disease described above, causality remains difficult to prove, but the temporal 
relationship between SARS-CoV-2 infection and the onset/diagnosis of demyelinating event is compelling 
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